|
1
|
Symmers WS: Thrombotic microangiopathic
haemolytic anaemia (thrombotic microangiopathy). Br Med J.
2:897–903. 1952. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anai H, Okada Y, Okubo K, Korenaga D,
Maehara Y, Sugimachi K and Ohi Y: A case report of hemolytic uremic
syndrome (HUS) induced by antineoplastic agents. Nihon Gan Chiryo
Gakkai Shi. 25:1487–1491. 1990.(In Japanese). PubMed/NCBI
|
|
3
|
Schjølseth SA, Hagen T, Ottestad L and
Jakobsen E: Chemotherapy-induced hemolytic uremic syndrome. A
complication to mitomycin treatment of breast carcinoma. Tidsskr
Nor Laegeforen. 115:3371–3373. 1995.(In Norwegian). PubMed/NCBI
|
|
4
|
Seo DW, Lee YS, Chae JG, Lee MG, Choe GY,
Chi HS and Min YI: Hepatocellular carcinoma associated hemolytic
uremic syndrome unrelated to chemotherapy. J Korean Med Sci.
9:254–258. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murgo AJ: Cancer- and
chemotherapy-associated thrombotic microangiopathyHemolytic-Uremic
Syndrome and Thrombotic Thrombocytopenic Purpura. Kaplan BS,
Trompeter RS and Moake JL: Marcel Dekker; New York, NY: pp.
271–285. 1992
|
|
6
|
Pisoni R, Ruggenenti P and Remuzzi G:
Drug-induced thrombotic microangiopathy: Incidence, prevention and
management. Drug Saf. 24:491–501. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lesesne JB, Rothschild N, Erickson B,
Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L and
Schein PS: Cancer-associated hemolytic-uremic syndrome: Analysis of
85 cases from a national registry. J Clin Oncol. 7:781–789.
1989.PubMed/NCBI
|
|
8
|
Hillyer CD, Duncan A, Ledford M, Barrett
TJ, Klumpp SA, Anderson DC, McClure HM and Winton EF:
Chemotherapy-induced hemolytic uremic syndrome: Description of a
potential animal model. J Med Primatol. 24:68–73. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feys HB, Roodt J, Vandeputte N, Pareyn I,
Lamprecht S, van Rensburg WJ, Anderson PJ, Budde U, Louw VJ,
Badenhorst PN, et al: Thrombotic thrombocytopenic purpura directly
linked with ADAMTS13 inhibition in the baboon (Papio ursinus).
Blood. 116:2005–2010. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lichtman LA, Beutler E, Kipps TJ,
Seligsohn U, Kaushansky K and Prchal JT: Williams Hematology. 7th.
Sydney: McGraw-Hill Medical. Sydney. 2006
|
|
11
|
Tsai HM: The molecular biology of
thrombotic microangiopathy. Kidney Int. 70:162006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Casper ES, Green MR, Kelsen DP, Heelan RT,
Brown TD, Flombaum CD, Trochanowski B and Tarassoff PG: Phase II
trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with
adenocarcinoma of the pancreas. Invest New Drugs. 12:29–34. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oberic L, Buffet M, Schwarzinger M,
Veyradier A, Clabault K, Malot S, Schleinitz N, Valla D, Galicier
L, Bengrine-Lefèvre L, et al: Cancer awareness in atypical
thrombotic microangiopathies. Oncologist. 14:769–779. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Walter RB, Joerger M and Pestalozzi BC:
Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis.
40:E162002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Humphreys BD, Sharman JP, Henderson JM,
Clark JW, Marks PW, Rennke HG, Zhu AX and Magee CC:
Gemcitabine-associated thrombotic microangiopathy. Cancer.
100:2664–2670. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fung MC, Storniolo AM, Nguyen B, Arning M,
Brookfield W and Vigil J: A review of hemolytic uremic syndrome in
patients treated with gemcitabine therapy. Cancer. 85:2023–2032.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
De Smet D, Jochmans K and Neyns B:
Development of thrombotic thrombocytopenic purpura after a single
dose of gemcitabine. Ann Hematol. 87:495–496. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sedlacek SM: First-line and salvage
therapy of metastatic breast cancer with mitomycin/vinblastine.
Oncology. 50:(Suppl 1). S16–S21. 1993. View Article : Google Scholar
|
|
19
|
Hollenbeck M, Kutkuhn B, Aul C, Leschke M,
Willers R and Grabensee B: Haemolytic-uraemic syndrome and
thrombotic-thrombocytopenic purpura in adults: Clinical findings
and prognostic factors for death and end-stage renal disease.
Nephrol Dial Transplant. 13:76–81. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sens YA, Miorin LA, Silva HG, Malheiros
DM, Filho DM and Jabur P: Acute renal failure due to hemolytic
uremic syndrome in adult patients. Ren Fail. 19:279–282. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sheldon R and Slaughter D: A syndrome of
microangiopathic hemolytic anemia, renal impairment, and pulmonary
edema in chemotherapy-treated patients with adenocarcinoma. Cancer.
58:1428–1436. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mergenthaler HG, Binsack T and Wilmanns W:
Carcinoma-associated hemolytic-uremic syndrome in a patient
receiving 5-fluorouracil-adriamycin-mitomycin C combination
chemotherapy. Oncology. 45:11–14. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Desramé J, Duvic C, Bredin C, Béchade D,
Artru P, Brézault C, Defuentes G, Poirier JM, Dourthe LM, Coutant
G, et al: Hemolytic uremic syndrome as a complication of
gemcitabine treatment: Report of six cases and review of the
literature. Rev Med Interne. 26:179–188. 2005.(In French).
View Article : Google Scholar : PubMed/NCBI
|
